AR085171A1 - Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contiene - Google Patents
Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contieneInfo
- Publication number
- AR085171A1 AR085171A1 ARP110101401A ARP110101401A AR085171A1 AR 085171 A1 AR085171 A1 AR 085171A1 AR P110101401 A ARP110101401 A AR P110101401A AR P110101401 A ARP110101401 A AR P110101401A AR 085171 A1 AR085171 A1 AR 085171A1
- Authority
- AR
- Argentina
- Prior art keywords
- water
- salt
- crystalline
- ralfinamide
- impurities
- Prior art date
Links
- BHJIBOFHEFDSAU-LBPRGKRZSA-N ralfinamide Chemical class C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1F BHJIBOFHEFDSAU-LBPRGKRZSA-N 0.000 title abstract 10
- 231100000024 genotoxic Toxicity 0.000 title abstract 7
- 230000001738 genotoxic effect Effects 0.000 title abstract 7
- 239000012535 impurity Substances 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 13
- 239000000203 mixture Substances 0.000 abstract 10
- 150000003839 salts Chemical class 0.000 abstract 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 7
- 125000004432 carbon atom Chemical group C* 0.000 abstract 7
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 abstract 7
- 239000002243 precursor Substances 0.000 abstract 6
- 239000013557 residual solvent Substances 0.000 abstract 6
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 5
- 239000007787 solid Substances 0.000 abstract 5
- 239000013078 crystal Substances 0.000 abstract 3
- 238000002425 crystallisation Methods 0.000 abstract 3
- 230000008025 crystallization Effects 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 150000007513 acids Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- 229940098779 methanesulfonic acid Drugs 0.000 abstract 2
- 238000000746 purification Methods 0.000 abstract 2
- 239000002002 slurry Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- -1 that is Chemical compound 0.000 abstract 2
- 238000004482 13C cross polarization magic angle spinning Methods 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 238000012926 crystallographic analysis Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10161207 | 2010-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085171A1 true AR085171A1 (es) | 2013-09-18 |
Family
ID=42634917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101401A AR085171A1 (es) | 2010-04-27 | 2011-04-25 | Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contiene |
Country Status (27)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE030504T2 (en) * | 2010-04-27 | 2017-05-29 | Newron Pharm Spa | Process for the preparation of ralfinamide methanesulfonate salts or their R-enantiomers |
| CN103804341B (zh) * | 2012-11-13 | 2018-04-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 酰胺衍生物及其医药用途 |
| CN104761531B (zh) * | 2014-01-03 | 2017-12-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 镇痛活性化合物及其医药用途 |
| CN104292128A (zh) * | 2014-07-01 | 2015-01-21 | 南京正科制药有限公司 | 一种沙芬酰胺晶型a |
| CN115368310B (zh) * | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| ATE317280T1 (de) | 2001-09-03 | 2006-02-15 | Newron Pharm Spa | Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung |
| EP1438956A1 (en) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
| WO2004066987A2 (en) * | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Use of sodium channel modulators for treating gastrointestinal tract disorders |
| AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| SI1658062T1 (sl) | 2003-08-25 | 2010-05-31 | Newron Pharm Spa | Alfa aminoamidni derivati uporabni kot protivnetna sredstva |
| EP1557166A1 (en) | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| DK1809271T5 (da) * | 2004-09-10 | 2010-12-06 | Newron Pharm Spa | Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer |
| EP1870097A1 (en) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| AU2007263328C1 (en) | 2006-06-19 | 2012-09-06 | Newron Pharmaceuticals S.P.A. | Process for the production of 2- [4 - ( 3- and 2-fluorobenzyloxy) benzylamino] propan amides |
| JP5315674B2 (ja) * | 2007-11-19 | 2013-10-16 | セントラル硝子株式会社 | 非水電池用電解液及びこれを用いた非水電池 |
| PT2229351T (pt) | 2007-12-11 | 2018-01-19 | Newron Pharm Spa | Processo para a produção de 2-[4-(3- ou 2-fluorobenziloxi)benzilamino]propanamidas com grau de pureza alto |
| ES2878063T3 (es) | 2007-12-19 | 2021-11-18 | Newron Pharm Spa | Derivados de la alfa-aminoamida para el tratamiento de trastornos psiquiátricos |
| WO2009109334A1 (en) | 2008-03-07 | 2009-09-11 | Newron Pharmaceuticals S.P.A. | (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain |
| HUE030504T2 (en) * | 2010-04-27 | 2017-05-29 | Newron Pharm Spa | Process for the preparation of ralfinamide methanesulfonate salts or their R-enantiomers |
-
2011
- 2011-04-06 HU HUE11714958A patent/HUE030504T2/en unknown
- 2011-04-06 ME MEP-2016-169A patent/ME02509B/me unknown
- 2011-04-06 BR BR112012027623-9A patent/BR112012027623B1/pt active IP Right Grant
- 2011-04-06 NZ NZ700221A patent/NZ700221A/en unknown
- 2011-04-06 EP EP11714958.3A patent/EP2563355B1/en active Active
- 2011-04-06 NZ NZ602648A patent/NZ602648A/en unknown
- 2011-04-06 KR KR1020127030931A patent/KR101851118B1/ko active Active
- 2011-04-06 DK DK11714958.3T patent/DK2563355T3/en active
- 2011-04-06 CN CN201510387405.XA patent/CN105037188B/zh active Active
- 2011-04-06 LT LTEP11714958.3T patent/LT2563355T/lt unknown
- 2011-04-06 PT PT117149583T patent/PT2563355T/pt unknown
- 2011-04-06 SI SI201130927A patent/SI2563355T1/sl unknown
- 2011-04-06 CN CN201180020748.2A patent/CN102858330B/zh active Active
- 2011-04-06 AU AU2011246707A patent/AU2011246707B2/en active Active
- 2011-04-06 HR HRP20161077TT patent/HRP20161077T1/hr unknown
- 2011-04-06 US US13/643,716 patent/US9505708B2/en active Active
- 2011-04-06 WO PCT/EP2011/055309 patent/WO2011134763A1/en not_active Ceased
- 2011-04-06 JP JP2013506566A patent/JP5808392B2/ja active Active
- 2011-04-06 MX MX2012012093A patent/MX342697B/es active IP Right Grant
- 2011-04-06 CA CA2794389A patent/CA2794389C/en active Active
- 2011-04-06 ES ES11714958.3T patent/ES2590128T3/es active Active
- 2011-04-06 PL PL11714958.3T patent/PL2563355T3/pl unknown
- 2011-04-06 EA EA201291116A patent/EA021389B1/ru unknown
- 2011-04-06 RS RS20160665A patent/RS55084B1/sr unknown
- 2011-04-18 TW TW100113339A patent/TWI492919B/zh active
- 2011-04-25 AR ARP110101401A patent/AR085171A1/es not_active Application Discontinuation
-
2012
- 2012-10-18 IL IL222532A patent/IL222532A/en active IP Right Grant
-
2015
- 2015-05-22 JP JP2015104930A patent/JP6345154B2/ja active Active
-
2016
- 2016-08-05 SM SM201600266T patent/SMT201600266B/it unknown
- 2016-08-10 CY CY20161100786T patent/CY1117879T1/el unknown
- 2016-10-12 US US15/291,202 patent/US9856207B2/en active Active
-
2017
- 2017-05-30 JP JP2017106571A patent/JP6450420B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2663663C2 (ru) | Соль омекамтива мекарбила и способ ее получения | |
| CU20120072A7 (es) | Proceso para la preparación del calcobutrol | |
| AR085171A1 (es) | Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contiene | |
| RU2627698C2 (ru) | Натриевая соль (2s, 5r)-6-бензилокси-7-оксо-1,6-диаза-бицикло[3.2.1]октан-2-карбоновой кислоты и ее получение | |
| US11352323B2 (en) | Processes for making, and methods of using, glycopyrronium compounds | |
| ES2745157T3 (es) | Un método para la preparación, aislamiento y purificación de formas farmacéuticamente aplicables de AHU-377 | |
| CN102249977A (zh) | 4-羟基-2-氧代-1-吡咯烷乙酰胺外消旋体晶型ⅰ及其制备方法 | |
| ES2879294T3 (es) | Formas polimórficas de Belinostat y procesos para la preparación de las mismas | |
| BR122021008946B1 (pt) | Composto em sua forma cristalina e processo para a preparação do mesmo | |
| ITMI20101239A1 (it) | Processo ed intermedi per la preparazione di un principio attivo | |
| ES2886495T3 (es) | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida y usos de las mismas | |
| CN108947989B (zh) | 氘代光学异构体及其医药用途 | |
| PT2532651E (pt) | Processo de síntese e forma cristalina docloridrato de 4-{3-[cishexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida bem como da base livre associada e das composições farmacêuticas que os contenham | |
| CN107090000A (zh) | 一种苯并硼唑7位脂肪酸的衍生物及其制备与药物用途 | |
| EA024825B1 (ru) | Сокристалл тикагрелора с 3-гидрокси-2-нафтойной кислотой, способ его получения и применение | |
| Hu et al. | Resolutions of sibutramine with enantiopure tartaric acid derivatives: chiral discrimination mechanism | |
| ES2383714T3 (es) | Proceso para preparar un compuesto (S)-1-alquil-2',6'-pipecoloxilidídico | |
| TW202024035A (zh) | 用於製備(-)-琥珀酸西苯唑啉的新穎方法 | |
| CN104130146A (zh) | (4s)-3,6,9-三氮杂-3,6,9-三(羧甲基)-4-(4-乙氧基苄基)十一烷二酸的制备方法 | |
| CA3170252A1 (en) | Pyrimidine compounds and their pharmaceutical uses | |
| FR2892721B1 (fr) | Nouveau procede de preparation de sels d'acides et d'ammonium quaternaires | |
| CA3030772C (en) | Processes for making, and methods of using, glycopyrronium compounds | |
| PT1968965E (pt) | Um método para a preparação de cloridrato de (s)-n-metil- 3-(1-naftiloxi)-3-((2-tienil)propilamina (duloxetina) | |
| ES2668771T3 (es) | Métodos para la producción de L-carnitina | |
| ES2669750T3 (es) | Un proceso para producir saxagliptina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |